Jean-Frederic Viret, Ph.D. Promoted to Vice President and Chief Financial
Officer; Richard P. Powers to Transition to Consultant Role
SOUTH SAN FRANCISCO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today reported 2007 fourth quarter and year-end financial results and accomplishments and outlined its objectives for 2008 based on commercialization plans for FDA-approved Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, as well as clinical development milestones for Adlea(TM), the company's long-acting, localized, non-opioid analgesic drug candidate.
"We are preparing on multiple fronts for a successful commercial introduction for Zingo in the second quarter by driving product demand through multiple initiatives and direct contact with our target customers," said John P. McLaughlin, chief executive officer of Anesiva. "We also have a very active clinical program with Adlea that includes two ongoing Phase 2 trials in post-surgical pain as well as plans to advance into two Phase 3 registration trials in post-surgical indications in the first half of 2008."
Recent Highlights and Accomplishments
Anesiva continued to execute on its corporate, commercial and clinical
milestones in late 2007 and early 2008:
-- Hired sales force of 15 regional account managers (RAMs) and two
directors targeting key pediatric hospitals to commercialize Zingo for
the approved patient population (three to 18 years of age). The RAMs
completed training and went into their territories at the end of
January. The Anesiva sales force will focus their efforts on creating
demand by educating nurses and physici
|SOURCE Anesiva, Inc.|
Copyright©2008 PR Newswire.
All rights reserved